Month: August 2020

LA JOLLA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigator, Lara Ray, PhD, Professor at the Department of Psychology, University of California Los Angeles (UCLA) presented the results of the Ibudilast and Alcohol Use Disorder Phase 2 trial at the American Psychological Association 2020 Annual Convention held online.The clinical trial is a collaborative effort between MediciNova and Dr. Lara Ray, Professor, Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute at UCLA and is funded by the Center for Study of Opioid Receptors and Drugs of Abuse (CSORDA; National Institute on Drug...

GAITHERSBURG, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020.Conference call details are as follows:Conference call and webcast replay:About NovavaxNovavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NVX‑CoV2373 was generally well-tolerated and elicited...

Revenue Growth of 17% on a Y/Y Basis Best Since Fourth Quarter 2015Variable Revenue Increased 89% on a Y/Y BasisAdjusted EBITDA Margin More than Tripled on a Y/Y Basis to 31%Cash Increased $8 Million Sequentially to $64 MillionRESEARCH TRIANGLE PARK, N.C., Aug. 06, 2020 (GLOBE NEWSWIRE) —  ChannelAdvisor Corporation (NYSE: ECOM), a leading provider of cloud-based e-commerce solutions that enable brands and retailers to increase global sales, today reported financial results for the quarter ended June 30, 2020.“Our second quarter results were exceptional, with record revenues and record adjusted EBITDA both substantially exceeding our original guidance for the quarter,” said David Spitz, ChannelAdvisor’s chief executive officer. “Strong revenues were driven by sustained and broad-based growth in GMV as e-commerce...

DUBLIN, Ireland and CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2020.“Based on data generated in our Phase 3 clinical program, we continue to believe that sulopenem can play a vital role in the treatment of infections caused by multi-drug resistant pathogens that have become prevalent in our community,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “We have been granted a meeting with the FDA at the end of the third quarter and plan to share the results of that meeting shortly thereafter.”Q2 2020 Highlights...

BROOKFIELD, News, Aug. 06, 2020 (GLOBE NEWSWIRE) — Brookfield Business Partners L.P. (NYSE: BBU) (TSX: BBU.UN) (“Brookfield Business Partners”) announced today financial results for the quarter ended June 30, 2020.“Our business faced challenging conditions during the second quarter as a result of the global economic shutdown. We addressed this unprecedented situation by rapidly reducing costs, maximizing liquidity and implementing measures to protect employees,” said Cyrus Madon, CEO of Brookfield Business Partners. “Activity levels at virtually all our operations increased as we entered the third quarter reflecting the essential nature of products and services that our businesses provide.”Brookfield Business Partners generated Company EBITDA of $286 million for the three months ended June 30, 2020 compared to $237 million...

MONACO, Aug. 06, 2020 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE: STNG) (“Scorpio Tankers” or the “Company”) today reported its results for the three and six months ended June 30, 2020.  The Company also announced that its Board of Directors has declared a quarterly cash dividend of $0.10 per share on the Company’s common stock.Results for the three months ended June 30, 2020 and 2019For the three months ended June 30, 2020, the Company had net income of $143.9 million, or $2.63 basic and $2.40 diluted earnings per share.  For the three months ended June 30, 2020, the Company had an adjusted net income (see Non-IFRS Measures section below) of $144.3 million, or $2.63 basic and $2.40 diluted earnings per share, which excludes from net income a $0.3 million, or $0.01 per basic and diluted share, write-off...